The Supreme Court last week unanimously affirmed a Federal Circuit decision finding that patent claims for Amgen's Repatha® that cover "the entire genus" of antagonist antibodies involved in regulating LDL cholesterol are invalid. The Court held that the patents at issue do not sufficiently enable a person of ordinary skill in the art to make and use the claimed invention as required by 35 U.S.C. § 112(a). This lawsuit, brought by Amgen against Sanofi and Regeneron, has captivated the life sciences industry for the past nine years.